Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...